Showing 1 - 6 results of 6 for search 'Atul Deodhar', query time: 0.01s Refine Results
  1. 1
    Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab

    Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab by Jan Brandt-Jürgens, Martin Rudwaleit, Frank Behrens, Christopher Ritchlin, Daniel Peterlik, Erhard Quebe-Fehling, Atul Deodhar

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

    Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and pr... by Peter Nash, Frank Behrens, Ana-Maria Orbai, Suchitrita S Rathmann, David H Adams, Olivier Benichou, Atul Deodhar

    Published 2018-09-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Divergent B-cell and cytotoxic TNK cell activation signatures in HLA-B27-associated ankylosing spondylitis and acute anterior uveitis

    Divergent B-cell and cytotoxic TNK cell activation signatures in HLA-B27-associated ankylosing spondylitis and acute anterior uveitis by Eisa Mahyari, Sean Davin, Kimberly Ogle, Emma Fale-Olsen, Carley Shaut, Tammy M. Martin, Jasvinder S. Ahuja, Eric Suhler, Atul Deodhar, James T. Rosenbaum, James T. Rosenbaum, Tejpal Gill, Tejpal Gill

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study

    Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3,... by Philip J. Mease, Xenofon Baraliakos, Vinod Chandran, Enrique R. Soriano, Peter Nash, Atul Deodhar, Emmanouil Rampakakis, Natalie J. Shiff, Soumya D. Chakravarty, May Shawi, Joseph F. Merola, Iain B. McInnes

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

    Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study by Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Xianwei Bu, Ivan Lagunes-Galindo, In-Ho Song, Peter Wung, Koji Kato, Anna Shmagel

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

    Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study... by Atul Deodhar, Shihong Sheng, Philip S Helliwell, Soumya D Chakravarty, Elizabeth C Hsia, Enrique R Soriano, Chetan S Karyekar, Wolf-Henning Boehncke, Prasheen Agarwal, Christopher T Ritchlin, Alexa P Kollmeier, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu, Qing C Zuraw, Yusang Jiang, Bei Zhou, Yanli Zhuang, May Shawi

    Published 2021-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: